RECRUITING

Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this study is to create a data set to add to Carevive's registry from real world clinical and patient reported data collected using an electronic care planning system (CPS) with remote symptom monitoring that is used in routine care for cancer patients on active treatment. Patients will complete a baseline survey in person using a secured device or remotely using their own electronic device in a location of their choice. Weekly electronic patient reported outcome (PRO) surveys are collected from the patients using the Carevive platform for a minimum of 12 weeks. Patients may continue weekly surveys as long as they are receiving treatment.

Official Title

Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia (AML) Using Remote Symptom Monitoring

Quick Facts

Study Start:2023-07-19
Study Completion:2024-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05974150

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * All participants must be 18 years of age or older.
  2. * Subjects may be any stage and anywhere in the treatment continuum.
  3. * Subject participants must have a diagnosis of a breast, lung, AML, ovarian cancer or multiple myeloma.
  4. * Subjects must be able to complete on-line surveys using a cell phone, tablet, or computer.
  5. * All participants must be able to understand English.
  1. * Any patient who cannot understand written or spoken English.
  2. * Any patient without the ability to complete on-line surveys using a cell phone, tablet, or computer.
  3. * Any patient on a treatment clinical trial.
  4. * Any prisoner and/or other vulnerable persons as defined by NIH (45 CFR 46, Subpart B, C and D).

Contacts and Locations

Study Contact

JULIE SCOTT, MSN
CONTACT
8778423210
Julie.Scott@Carevive.com

Study Locations (Sites)

Yale Cancer Center
New Haven, Connecticut, 06511
United States
Northshore University Health System
Evanston, Illinois, 31024
United States
Univeristy of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599
United States
Duke
Durham, North Carolina, 27707
United States
Cleveland Clinic Mercy Hospital
Canton, Ohio, 44708
United States
University Hospitals Seidman Cancer Center
Cleveland, Ohio, 44106
United States
Tri-County Hematology & Oncology Associates, Inc.
Massillon, Ohio, 44646
United States

Collaborators and Investigators

Sponsor: Carevive Systems, Inc.

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-07-19
Study Completion Date2024-12-31

Study Record Updates

Study Start Date2023-07-19
Study Completion Date2024-12-31

Terms related to this study

Additional Relevant MeSH Terms

  • Breast Cancer
  • Lung Cancer
  • Multiple Myeloma
  • Ovarian Cancer
  • Acute Myelogenous Leukemia